-
GSH-Responsive MOF Nanoparticles for Melanoma Therapy
2026-09-03
Hao and colleagues developed ICG-MOF-SS-AUNP12, a glutathione-responsive metal-organic framework nanoparticle that combines photothermal ablation with localized PD-1/PD-L1 blockade. The study shows how 808 nm irradiation, redox-triggered peptide release, and immune activation can be integrated into one melanoma-oriented nanoplatform, while also highlighting the validation needed before substituting related dyes such as IR-820.
-
4-Hydroxytamoxifen: Protocol and QC Guide
2026-09-02
4-Hydroxytamoxifen is a DMSO-compatible estrogen receptor modulator for controlled cell, cancer, cardiac myocyte, and selected mouse-model workflows. It should not be selected for protocols requiring water or ethanol as the primary solvent, and long-term storage of prepared solutions should be avoided.
-
CDK9 inhibitor A3294: Practical Workflow Guide
2026-09-02
CDK9 inhibitor A3294 provides a selective serine/threonine kinase inhibitor for examining CDK9-dependent transcription elongation, P-TEFb activity, and exploratory HIV-1 propagation assays. The available evidence is limited to the product dossier, so it should be validated in the intended assay and should not be treated as a pan-CDK reagent, universal cytotoxicity control, or therapeutic predictor.
-
Leupeptin: Precision Protease Control in Translation
2026-09-01
Leupeptin hemisulfate salt is more than a conventional protease-blocking reagent. Its reversible, competitive mechanism provides a controllable way to interrogate protein degradation, autophagy, and selected viral replication workflows, while a modern TET2 metabolite-binding protocol offers a useful model for orthogonal validation and translational assay design.
-
RepSox: ALK5 Inhibition in iPSC Workflows
2026-09-01
RepSox is a potent and selective ALK5 inhibitor for studying TGF-β signaling, induced pluripotent stem cell reprogramming, and cell differentiation. Its reported 4 nM ALK5 inhibition supports pathway-focused experiments, but current hiPSC-derived platelet benchmarks do not establish RepSox as a validated platelet-differentiation reagent.
-
Liproxstatin-1 in Ferroptosis Assay Design
2026-08-31
Liproxstatin-1 is a potent ferroptosis inhibitor for testing whether lipid peroxidation drives cell injury. This guide connects its validated rescue profile with a sex-specific salivary gland study and offers a causal, tissue-aware assay strategy.
-
0.4% Trypan Blue Solution: Practical Guide
2026-08-31
0.4% Trypan Blue Solution supports rapid cell viability measurement by differentiating unstained viable cells from blue-stained dead or membrane-damaged cells during cell counting. It is suitable for research workflows and cytotoxicity assays, but it should not be used for diagnostic purposes or as a standalone method for mechanistic apoptosis and necrosis detection.
-
Primary Antibody Dilution Buffer for PCNSL
2026-08-30
Learn how Primary Antibody Dilution Buffer supports spatial validation of PCNSL metabolic discoveries. This article connects single-cell evidence on SLC2A5 with practical IHC, ICC, and antibody-dependent ISH assay design.
-
Novobiocin: From Mechanism to Translation
2026-08-29
A translational strategy for using Novobiocin as a mechanistically rich aminocoumarin antibiotic across antibacterial resistance research, parasitic disease, antiviral discovery, and apoptosis-focused workflows.
-
Complete Nicotine Biosynthesis: A Vacuolar Metabolon
2026-08-28
Chang et al. resolve the final steps of nicotine biosynthesis by identifying a glycosylation-dependent, stereoselective Mannich-like condensation and a vacuolar five-component metabolon that coordinates pathway chemistry with transport. The study combines omics, biochemical reconstitution, pathway perturbation, and heterologous plant engineering to establish a transferable framework for nicotine production and pest-resistance research.
-
Molnupiravir Protects Mice from Bourbon Virus Disease
2026-08-28
Bamunuarachchi and colleagues show that molnupiravir inhibits Bourbon virus replication in vitro and protects susceptible mice from lethal disease when given before or after infection. The study is notable for linking antiviral activity with reduced tissue viral burden, improved thrombocytopenia, restored splenic immune profiles, and less liver and spleen pathology.
-
Stattic: STAT3 Inhibitor for Cancer Research
2026-08-27
Stattic is a small-molecule STAT3 inhibitor that disrupts STAT3 dimerization and nuclear signaling. Product data support micromolar activity in HNSCC models, while independent evidence shows that Stattic can block cadmium-induced STAT3 responses in lymphatic endothelial cells.
-
Clarithromycin CYP3A Inhibitor Workflow
2026-08-27
Build reproducible CYP3A inhibition assays with Clarithromycin for statin metabolism interaction, cardiovascular disease drug interaction, and broader drug-drug interaction research. This workflow combines solvent-aware preparation, pathway-negative comparison, quantitative readouts, and troubleshooting for translational pharmacokinetic studies.
-
Triamcinolone Research Workflow Guide
2026-08-26
Triamcinolone (SKU B1859) provides a defined synthetic glucocorticoid agonist for controlled in vitro studies of glucocorticoid receptor signaling, inflammation, and immunosuppression. This guide addresses solvent selection, storage, assay controls, and quality checks; the compound is for scientific research only and should not be used for diagnostic, therapeutic, or clinical applications.
-
NSP15 Screening Finds Thymopentin and Oleuropein
2026-08-26
This 2021 structure-based study screened a natural-product library against the SARS-CoV-2 endoribonuclease NSP15 and identified thymopentin and oleuropein as the highest-ranked candidates. Molecular-dynamics analysis supported stable protein–ligand complexes, but the findings remain computational and require biochemical, cellular, and infection-model validation.